KY1103

KY1103 is a small molecule therapeutic candidate currently in preclinical development by KYDES Pharmaceuticals. It is being investigated for a broad spectrum of gynecological conditions, including malignancies such as cervical, vaginal, and uterine cancers, as well as benign but clinically significant disorders like endometriosis, adenomyosis, uterine fibroids, and heavy menstrual bleeding. Additionally, it is being explored for the treatment of cervical dysplasia. While the specific molecular target and mechanism of action have not been publicly disclosed by the developer, the drug represents a multi-indication approach to addressing unmet needs in women's health and gynecological oncology.